LCTX — Lineage Cell Therapeutics Share News
0.000.00%
Last trade - 00:00- $252.91m
- $201.01m
- $14.56m
Lineage Cell rises as eye treatment succeeds in early stage trial
Brief: Rg6501 (Opregen®) Phase 1/2A Results Show Evidence Of Rapid Improvement Of Outer Retinal Structure
BrainStorm Cell falls on FDA concerns over ALS therapy
Brief: Lineage Cell Therapeutics To Report Q2 Financial Results On August 10
Brief: Lineage Cell Therapeutics And Cancer Research UK Report Phase 1 Study Results With Vac2
Brief: Lineage Cell Therapeutics Expected To Be Added To Russell 3000 Index
Brief: Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results
Brief: Rg6501 (Opregen®) Phase 1/2A Clinical Results To Be Presented At 2023 Retinal Cell And Gene Therapy Innovation Summit
Brief: Lineage Cell Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: Lineage Enters Into Option And License Agreement With Eterna Therapeutics
Brief: Lineage Provides Update On Hearing Loss Treatment Program
Brief: Lineage Announces Launch Of Phase 2A Study By Genentech Of Rg6501 (Opregen®) In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration
Brief: Lineage Cell Therapeutics Inc Reports Q3 Loss Per Share Of $0.04
Brief: Lineage Cell Therapeutics Appoints Jill Howe As Chief Financial Officer
Brief: Neage Announces Notice Of Allowance Of Two Patents Covering Processes For Manufacturing Allogeneic Oligodendrocyte Progenitor And Retinal Pigmented Epithelium Cells
Brief: Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results
Brief: Lineage Cell Therapeutics Says Kevin L. Cook Would Be Resigning As CFO Effective July 8
Brief: Lineage Cell Therapeutics Reports Q1 2022 Results
Brief: RG6501 (Opregen) Phase 1/2A Clinical Results Support Potential For Opregen To Slow, Stop Or Reverse Disease Progression In Geographic Atrophy Secondary To Age-Related Macular Degeneration